Intel Corp vs Revvity Inc — how do they compare? Intel Corp trades at $100.85 (market cap $492.85B), while Revvity Inc trades at $115.97 (market cap $12.91B). The key difference: Intel Corp is far larger — about 38.2× Revvity Inc's market cap, and Intel Corp pays the higher dividend (2.24%). Which is the better fit depends on your goals.
| INTC | RVTY | |
|---|---|---|
Market Cap | $492.85B | $12.91B |
Volume | 43,552,012 | — |
Sector | Technology | Technology |
52-Week High | $140.94 | $117.75 |
52-Week Low | $21.81 | $82.26 |
Enterprise Value | $513.66B | $15.23B |
Dividend Yield | 2.24% | 0.24% |
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $100.51, up 3.07% today, with a bullish technical signal and recent earnings beats. Revenue grew 25% year-over-year in Q2 2026, driven by data center and AI segments, though net income margins remain negative. The company recently upsized a stock offering to $20 billion to fund AI and manufacturing investments, causing some investor concern over dilution but supporting long-term growth initiatives.
Outlook is mixed: strong revenue growth and analyst consensus price target of $116.67 suggest upside, but high valuation ratios, negative profitability, and execution risks in the capital-intensive foundry business pose challenges. Investor sentiment is cautiously optimistic amid the AI-driven turnaround narrative.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Trailing returns across standard periods
Latest headlines on both assets
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →